

# Olivier Cussenot

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7139096/publications.pdf>

Version: 2024-02-01

168  
papers

9,343  
citations

44042

48  
h-index

45285

90  
g-index

177  
all docs

177  
docs citations

177  
times ranked

11392  
citing authors

#	ARTICLE	IF	CITATIONS
1	Performance of African-ancestry-specific polygenic hazard score varies according to local ancestry in 8q24. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 229-237.	2.0	9
2	A Rare Germline HOXB13 Variant Contributes to Risk of Prostate Cancer in Men of African Ancestry. <i>European Urology</i> , 2022, 81, 458-462.	0.9	22
3	Bladder carcinomas in patients with neurogenic bladder and urinary schistosomiasis: are they the same tumors?. <i>World Journal of Urology</i> , 2022, 40, 1949-1959.	1.2	6
4	A study of the immunohistochemical profile of bladder cancer in neuro-urological patients by the French Association of Urology. <i>World Journal of Urology</i> , 2022, , 1.	1.2	2
5	Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 755-761.	2.0	14
6	Incidence of bladder cancer in neuro-urological patients in France: a nationwide study. <i>World Journal of Urology</i> , 2022, 40, 1921-1927.	1.2	6
7	T1G1 Bladder Cancer: Prognosis for this Rare Pathological Diagnosis Within the Non-muscle-invasive Bladder Cancer Spectrum. <i>European Urology Focus</i> , 2022, , .	1.6	4
8	DNA damage repair gene germline profiling for metastatic prostate cancer patients of different ancestries. <i>Prostate</i> , 2022, 82, 1196-1201.	1.2	2
9	A four-antibody immunohistochemical panel can distinguish clinico-pathological clusters of urothelial carcinoma and reveals high concordance between primary tumor and lymph node metastases. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 478, 637-645.	1.4	17
10	African-specific improvement of a polygenic hazard score for age at diagnosis of prostate cancer. <i>International Journal of Cancer</i> , 2021, 148, 99-105.	2.3	24
11	Genetic variability in 13q33 and 9q34 is linked to aggressiveness patterns and a higher risk of progression of non-muscle-invasive bladder cancer at the time of diagnosis. <i>BJU International</i> , 2021, 127, 375-383.	1.3	2
12	Diagnosis of prostate cancer in one day: The benefits of cytology in tumour detection. <i>Cytopathology</i> , 2021, 32, 211-216.	0.4	0
13	Postoperative assessment of nosocomial transmission of COVID-19 after robotic surgical procedures during the pandemic. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 298.e7-298.e11.	0.8	6
14	Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. <i>Nature Genetics</i> , 2021, 53, 65-75.	9.4	264
15	Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer. <i>Modern Pathology</i> , 2021, 34, 1185-1193.	2.9	61
16	Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 532-541.	2.0	16
17	Polygenic hazard score is associated with prostate cancer in multi-ethnic populations. <i>Nature Communications</i> , 2021, 12, 1236.	5.8	40
18	Bayesian predictive model to assess BRCA2 mutational status according to clinical history: Early onset, metastatic phenotype or family history of breast/ovary cancer. <i>Prostate</i> , 2021, 81, 318-325.	1.2	7

#	ARTICLE	IF	CITATIONS
19	Limiting radiation exposure during prostatic arteries embolization: influence of patient characteristics, anatomical conditions, and technical factors. <i>European Radiology</i> , 2021, 31, 6471-6479.	2.3	11
20	Pathological reporting of cystectomy lymph nodes: a retrospective analysis of experience in Paris. <i>World Journal of Urology</i> , 2021, 39, 4029-4035.	1.2	2
21	Assessment of Xpert Bladder Cancer Monitor test performance for the detection of recurrence during non-muscle invasive bladder cancer follow-up. <i>World Journal of Urology</i> , 2021, 39, 3329-3335.	1.2	19
22	Clinical practice guidelines for BRCA1 and BRCA2 genetic testing. <i>European Journal of Cancer</i> , 2021, 146, 30-47.	1.3	81
23	Restaging the Biochemical Recurrence of Prostate Cancer with [68Ga]Ga-PSMA-11 PET/CT: Diagnostic Performance and Impact on Patient Disease Management. <i>Cancers</i> , 2021, 13, 1594.	1.7	10
24	“Virtually Perfect” for Some but Perhaps Not for All: Launching Telemedicine in the Bronx during the COVID-19 Pandemic. Letter.. <i>Journal of Urology</i> , 2021, 206, 176-177.	0.2	1
25	Marital status and prostate cancer incidence: a pooled analysis of 12 case-control studies from the PRACTICAL consortium. <i>European Journal of Epidemiology</i> , 2021, 36, 913-925.	2.5	23
26	Rare Germline Variants in ATM Predispose to Prostate Cancer: A PRACTICAL Consortium Study. <i>European Urology Oncology</i> , 2021, 4, 570-579.	2.6	38
27	PD-L1 (SP142) testing is concordant between Benchmark Ultra and Bond-III stainers. <i>World Journal of Urology</i> , 2021, 39, 4067-4071.	1.2	2
28	Prognostic Impact of pT3 Subclassification in a Multicentre Cohort of Patients with Urothelial Carcinoma of the Renal Pelvic/ureteric System Undergoing Radical Nephroureterectomy: A Propensity Score-weighted Analysis After Central Pathology Review. <i>European Urology Focus</i> , 2021, 7, 1075-1083.	1.6	5
29	Papillary urothelial neoplasm of low malignant potential (PUN-LMP): Still a meaningful histo-pathological grade category for Ta, noninvasive bladder tumors in 2019?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 440-448.	0.8	27
30	Prostate cancer local staging using biparametric MRI: assessment and comparison with multiparametric MRI. <i>European Journal of Radiology</i> , 2020, 132, 109350.	1.2	23
31	Urology surgical activity and COVID-19: risk assessment at the epidemic peak: a Parisian multicentre experience. <i>BJU International</i> , 2020, 126, 436-440.	1.3	13
32	The Genetic Complexity of Prostate Cancer. <i>Genes</i> , 2020, 11, 1396.	1.0	9
33	The CHEK2 Variant C.349A>G Is Associated with Prostate Cancer Risk and Carriers Share a Common Ancestor. <i>Cancers</i> , 2020, 12, 3254.	1.7	16
34	A Germline Variant at 8q24 Contributes to Familial Clustering of Prostate Cancer in Men of African Ancestry. <i>European Urology</i> , 2020, 78, 316-320.	0.9	32
35	Testosterone replacement therapy (TRT) and prostate cancer: An updated systematic review with a focus on previous or active localized prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 661-670.	0.8	24
36	68Ga-PSMA-11 PET/CT in restaging castration-resistant nonmetastatic prostate cancer: detection rate, impact on patients’ disease management and adequacy of impact. <i>Scientific Reports</i> , 2020, 10, 2104.	1.6	33

#	ARTICLE	IF	CITATIONS
37	Transurethral resection of bladder and radical cystectomy: Concordance of histology. Are we good enough?. Turkish Journal of Urology, 2020, 46, 354-359.	1.3	4
38	Sex specific associations in genome wide association analysis of renal cell carcinoma. European Journal of Human Genetics, 2019, 27, 1589-1598.	1.4	27
39	The influence of obesity-related factors in the etiology of renal cell carcinoma—A mendelian randomization study. PLoS Medicine, 2019, 16, e1002724.	3.9	59
40	Impact of sodium 18F-fluoride PET/CT, 18F-fluorocholine PET/CT and whole-body diffusion-weighted MRI on the management of patients with prostate cancer suspicious for metastasis: a prospective multicentre study. World Journal of Urology, 2019, 37, 1587-1595.	1.2	10
41	Bladder mapping of tumour recurrence after radical nephroureterectomy for upper tract urothelial carcinoma and its influence on oncological outcomes. BJU International, 2019, 123, 618-623.	1.3	7
42	Mutational Profile of Aggressive, Localised Prostate Cancer from African Caribbean Men Versus European Ancestry Men. European Urology, 2019, 75, 11-15.	0.9	32
43	Comparison of cell cycle progression score with two immunohistochemical markers (PTEN and Ki-67) for predicting outcome in prostate cancer after radical prostatectomy. World Journal of Urology, 2018, 36, 1495-1500.	1.2	25
44	Typology of intravesical prostatic protrusions, or so-called median lobes, in middle-aged and older men. Surgical and Radiologic Anatomy, 2018, 40, 389-393.	0.6	5
45	Prevalence, management, and prognosis of bladder cancer in patients with neurogenic bladder: A systematic review. Neurourology and Urodynamics, 2018, 37, 1386-1395.	0.8	50
46	Two-photon optical imaging, spectral and fluorescence lifetime analysis to discriminate urothelial carcinoma grades. Journal of Biophotonics, 2018, 11, e201800065.	1.1	17
47	Guidelines for reporting secondary findings of genome sequencing in cancer genes: the SFMPP recommendations. European Journal of Human Genetics, 2018, 26, 1732-1742.	1.4	44
48	Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. Nature Communications, 2018, 9, 2256.	5.8	88
49	Analysis of bladder cancer subtypes in neurogenic bladder tumors. Canadian Journal of Urology, 2018, 25, 9161-9167.	0.0	9
50	Contemporary role of lymph node dissection at the time of radical nephroureterectomy for upper tract urothelial carcinoma. World Journal of Urology, 2017, 35, 535-548.	1.2	51
51	Correlation between prostate volume and single nucleotide polymorphisms implicated in the steroid pathway. World Journal of Urology, 2017, 35, 293-298.	1.2	10
52	Genome-wide association study identifies multiple risk loci for renal cell carcinoma. Nature Communications, 2017, 8, 15724.	5.8	106
53	Genetic Variants Related to Longer Telomere Length are Associated with Increased Risk of Renal Cell Carcinoma. European Urology, 2017, 72, 747-754.	0.9	39
54	Current perspectives of sentinel lymph node dissection at the time of radical surgery for prostate cancer. Cancer Treatment Reviews, 2016, 50, 228-239.	3.4	12

#	ARTICLE	IF	CITATIONS
55	Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer. <i>BMC Cancer</i> , 2016, 16, 704.	1.1	60
56	A comprehensive review of genomic landscape, biomarkers and treatment sequencing in castration-resistant prostate cancer. <i>Cancer Treatment Reviews</i> , 2016, 48, 25-33.	3.4	22
57	Oncologic Outcomes of Kidney Sparing Surgery versus Radical Nephroureterectomy for the Elective Treatment of Clinically Organ Confined Upper Tract Urothelial Carcinoma of the Distal Ureter. <i>Journal of Urology</i> , 2016, 195, 1354-1361.	0.2	30
58	Impact of Body Mass Index, Age, Prostate Volume, and Genetic Polymorphisms on Prostate-specific Antigen Levels in a Control Population. <i>European Urology</i> , 2016, 70, 6-8.	0.9	11
59	Identification of a novel susceptibility locus at 13q34 and refinement of the 20p12.2 region as a multi-signal locus associated with bladder cancer risk in individuals of European ancestry. <i>Human Molecular Genetics</i> , 2016, 25, 1203-1214.	1.4	38
60	Apparent diffusion coefficient value is a strong predictor of unsuspected aggressiveness of prostate cancer before radical prostatectomy. <i>World Journal of Urology</i> , 2016, 34, 1389-1395.	1.2	16
61	HOXB13 protein expression in metastatic lesions is a promising marker for prostate origin. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 468, 619-622.	1.4	16
62	Relationship between non-suspicious MRI and insignificant prostate cancer: results from a monocentric study. <i>World Journal of Urology</i> , 2016, 34, 673-678.	1.2	14
63	Accuracy of Magnetic Resonance Imaging/Ultrasound Fusion Targeted Biopsies to Diagnose Clinically Significant Prostate Cancer in Enlarged Compared to Smaller Prostates. <i>Journal of Urology</i> , 2015, 194, 669-673.	0.2	61
64	First round of targeted biopsies using magnetic resonance imaging/ultrasonography fusion compared with conventional transrectal ultrasonography-guided biopsies for the diagnosis of localised prostate cancer. <i>BJU International</i> , 2015, 115, 50-57.	1.3	146
65	Forkhead box protein P3 (Foxp3) expression serves as an early chronic inflammation marker of squamous cell differentiation and aggressive pathology of urothelial carcinomas in neurological patients. <i>BJU International</i> , 2015, 115, 28-32.	1.3	10
66	Low circulating free and bioavailable testosterone levels as predictors of high-grade tumors in patients undergoing radical prostatectomy for localized prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 384.e21-384.e27.	0.8	29
67	Clinicopathological characteristics of urothelial bladder cancer in patients less than 40 years old. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2015, 466, 589-594.	1.4	125
68	Immediate Nephroureterectomy or After Attempting Conservative Treatment, on Elective Indications, for Upper Urinary Tract Urothelial Carcinoma: Comparison of the Pathology Reports on a Retrospective Monocentric Study. <i>Journal of Endourology</i> , 2015, 29, 969-973.	1.1	9
69	Functional magnetic resonance imaging and molecular pathology at the crossroad of the management of early prostate cancer. <i>World Journal of Urology</i> , 2015, 33, 929-936.	1.2	7
70	Accuracy of the prostate health index versus the urinary prostate cancer antigen 3 score to predict overall and significant prostate cancer at initial biopsy. <i>Prostate</i> , 2015, 75, 103-111.	1.2	49
71	The Diagnostic and Prognostic Performance of Urinary FGFR3 Mutation Analysis in Bladder Cancer Surveillance: A Prospective Multicenter Study. <i>Urology</i> , 2015, 86, 1185-1191.	0.5	27
72	Multiparametric Magnetic Resonance Imaging Predicts Postoperative Pathology but Misses Aggressive Prostate Cancers as Assessed by Cell Cycle Progression Score. <i>Journal of Urology</i> , 2015, 194, 1617-1623.	0.2	30

#	ARTICLE	IF	CITATIONS
73	A Systematic Review and Meta-analysis of Clinicopathologic Factors Linked to Intravesical Recurrence After Radical Nephroureterectomy to Treat Upper Tract Urothelial Carcinoma. <i>European Urology</i> , 2015, 67, 1122-1133.	0.9	218
74	Characterization of long non-coding RNA transcriptome in clear-cell renal cell carcinoma by next-generation deep sequencing. <i>Molecular Oncology</i> , 2015, 9, 32-43.	2.1	75
75	Influence of preoperative factors on the oncologic outcome for upper urinary tract urothelial carcinoma after radical nephroureterectomy. <i>World Journal of Urology</i> , 2015, 33, 335-341.	1.2	42
76	Influence of statin use on clinicopathological characteristics of localized prostate cancer and outcomes obtained after radical prostatectomy: a single center study. <i>Canadian Journal of Urology</i> , 2015, 22, 7703-8.	0.0	7
77	Postoperative nomogram to predict cancer-specific survival after radical nephroureterectomy in patients with localised and/or locally advanced upper tract urothelial carcinoma without metastasis. <i>BJU International</i> , 2014, 114, 733-740.	1.3	62
78	Malnourishment in bladder cancer and the role of immunonutrition at the time of cystectomy: an overview for urologists. <i>BJU International</i> , 2014, 114, 177-184.	1.3	22
79	Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. <i>Human Molecular Genetics</i> , 2014, 23, 6616-6633.	1.4	90
80	Impact of micropapillary histological variant on survival after radical nephroureterectomy for upper tract urothelial carcinoma. <i>World Journal of Urology</i> , 2014, 32, 531-537.	1.2	28
81	Charlson score as a single pertinent criterion to select candidates for active surveillance among patients with small renal masses. <i>World Journal of Urology</i> , 2014, 32, 513-518.	1.2	10
82	Risk stratification of metastatic recurrence in invasive upper urinary tract carcinoma after radical nephroureterectomy without lymphadenectomy. <i>World Journal of Urology</i> , 2014, 32, 507-512.	1.2	13
83	Impact of the length of time between diagnosis and surgical removal of urologic neoplasms on survival. <i>World Journal of Urology</i> , 2014, 32, 475-479.	1.2	51
84	Detection of specific chromosomal aberrations in urine using BCA-1 (oligo-CGH-array) enhances diagnostic sensitivity and predicts the aggressiveness of non-muscle-invasive bladder transitional cell carcinoma. <i>World Journal of Urology</i> , 2014, 32, 551-557.	1.2	6
85	Genome-wide interaction study of smoking and bladder cancer risk. <i>Carcinogenesis</i> , 2014, 35, 1737-1744.	1.3	50
86	Genome-wide association study identifies multiple loci associated with bladder cancer risk. <i>Human Molecular Genetics</i> , 2014, 23, 1387-1398.	1.4	137
87	Secondary chemoprevention of localized prostate cancer by short-term androgen deprivation to select indolent tumors suitable for active surveillance: a prospective pilot phase II study. <i>World Journal of Urology</i> , 2014, 32, 545-550.	1.2	10
88	Comparison of oncologic outcomes after radical prostatectomy in men diagnosed with prostate cancer with PSA levels below and above 4 ng/mL. <i>World Journal of Urology</i> , 2014, 32, 481-487.	1.2	2
89	Germline Genetic Variations at 11q13 and 12p11 Locus Modulate Age at Onset for Renal Cell Carcinoma. <i>Journal of Urology</i> , 2014, 191, 487-492.	0.2	9
90	Hereditary-like urothelial carcinomas of the upper urinary tract benefit more from adjuvant cisplatin-based chemotherapy after radical nephroureterectomy than do sporadic tumours. <i>BJU International</i> , 2014, 113, 574-580.	1.3	18

#	ARTICLE	IF	CITATIONS
91	The 19q12 Bladder Cancer GWAS Signal: Association with Cyclin E Function and Aggressive Disease. <i>Cancer Research</i> , 2014, 74, 5808-5818.	0.4	24
92	The surgical approach can be determined from the pathological specimen obtained after open or robot-assisted laparoscopic radical prostatectomy. <i>World Journal of Urology</i> , 2014, 32, 489-493.	1.2	2
93	Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer. <i>Prostate</i> , 2013, 73, 242-249.	1.2	72
94	Current role of image-guided robotic radiosurgery (Cyberknife®) for prostate cancer treatment. <i>BJU International</i> , 2013, 111, 761-766.	1.3	19
95	Different subtypes of carcinoma in situ of the bladder do not have a different prognosis. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2013, 462, 343-348.	1.4	15
96	The role of chemotherapy in the treatment of urothelial cell carcinoma of the upper urinary tract (UUT-UCC). <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 407-413.	0.8	83
97	HOXB13 is a sensitive and specific marker of prostate cells, useful in distinguishing between carcinomas of prostatic and urothelial origin. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2013, 463, 803-809.	1.4	31
98	Genetic polymorphisms on 8q24.1 and 4p16.3 are not linked with urothelial carcinoma of the bladder in contrast to their association with aggressive upper urinary tract tumours. <i>World Journal of Urology</i> , 2013, 31, 53-59.	1.2	19
99	Intravesical recurrence after radical nephroureterectomy for upper tract urothelial carcinomas: predictors and impact on subsequent oncological outcomes from a national multicenter study. <i>World Journal of Urology</i> , 2013, 31, 61-68.	1.2	72
100	The impact of lymph node status and features on oncological outcomes in urothelial carcinoma of the upper urinary tract (UTUC) treated by nephroureterectomy. <i>World Journal of Urology</i> , 2013, 31, 189-197.	1.2	57
101	A systematic review of the tools available for predicting survival and managing patients with urothelial carcinomas of the bladder and of the upper tract in a curative setting. <i>World Journal of Urology</i> , 2013, 31, 109-116.	1.2	19
102	Detection of Bladder Urothelial Carcinoma Using In Vivo Noncontact, Ultraviolet Excited Autofluorescence Measurements Converted into Simple Color Coded Images: A Feasibility Study. <i>Journal of Urology</i> , 2013, 190, 271-277.	0.2	25
103	8q24 amplification is associated with Myc expression and prostate cancer progression and is an independent predictor of recurrence after radical prostatectomy. <i>Human Pathology</i> , 2013, 44, 1617-1623.	1.1	69
104	Prediction of Cancer Specific Survival After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: Development of an Optimized Postoperative Nomogram Using Decision Curve Analysis. <i>Journal of Urology</i> , 2013, 189, 1662-1669.	0.2	152
105	Impact of lymphovascular invasion on oncological outcomes in patients with upper tract urothelial carcinoma after radical nephroureterectomy. <i>BJU International</i> , 2013, 111, 1199-1207.	1.3	40
106	Genetic Variability in 8q24 Confers Susceptibility to Urothelial Carcinoma of the Upper Urinary Tract and is Linked With Patterns of Disease Aggressiveness at Diagnosis. <i>Journal of Urology</i> , 2012, 187, 424-428.	0.2	27
107	Clinical characteristics and pathologic findings in patients eligible for active surveillance who underwent radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2012, 30, 402-407.	0.8	7
108	Impact of the expression of Aurora-A, p53, and MIB-1 on the prognosis of urothelial carcinomas of the upper urinary tract. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2012, 30, 182-187.	0.8	25

#	ARTICLE	IF	CITATIONS
109	A genome-wide association study identifies a novel susceptibility locus for renal cell carcinoma on 12p11.23. <i>Human Molecular Genetics</i> , 2012, 21, 456-462.	1.4	81
110	Quantitative RT-PCR analysis of PSA and prostate-specific membrane antigen mRNA to detect circulating tumor cells improves recurrence-free survival nomogram prediction after radical prostatectomy. <i>Prostate</i> , 2012, 72, 1382-1388.	1.2	34
111	Persistently elevated prostate-specific antigen at six weeks after radical prostatectomy helps in early identification of patients who are likely to recur. <i>World Journal of Urology</i> , 2012, 30, 239-244.	1.2	28
112	Potential role of photodynamic techniques combined with new generation flexible ureterorenoscopes and molecular markers for the management of urothelial carcinoma of the upper urinary tract. <i>BJU International</i> , 2012, 109, 608-613.	1.3	37
113	Is there a contemporary role for percutaneous needle biopsy in the era of small renal masses?. <i>BJU International</i> , 2012, 109, 867-872.	1.3	36
114	Genetic pathways involved in carcinogenesis of clear cell renal cell carcinoma: genomics towards personalized medicine. <i>BJU International</i> , 2012, 109, 1864-1870.	1.3	56
115	A proportion of hereditary upper urinary tract urothelial carcinomas are misclassified as sporadic according to a multi-institutional database analysis: proposal of patient-specific risk identification tool. <i>BJU International</i> , 2012, 110, E583-9.	1.3	68
116	Bladder recurrence after surgery for upper urinary tract urothelial cell carcinoma: Frequency, risk factors, and surveillance. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2011, 29, 130-136.	0.8	135
117	Oncologic control obtained after radical prostatectomy in men with a pathological Gleason score $\geq 8$ : A single-center experience. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2011, 29, 602-607.	0.8	6
118	Impact of Genotyping on Outcome of Prostatic Biopsies: A Multicenter Prospective Study. <i>Molecular Medicine</i> , 2011, 17, 473-477.	1.9	7
119	Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3. <i>Nature Genetics</i> , 2011, 43, 60-65.	9.4	220
120	Diagnostic, Staging, and Grading of Urothelial Carcinomas from Urine: Performance of BCA-1, a Mini-Array Comparative Genomic Hybridisation-Based Test. <i>European Urology</i> , 2011, 59, 250-257.	0.9	19
121	From Active Surveillance to the Concept of Secondary Prevention. <i>European Urology</i> , 2011, 59, 568-571.	0.9	11
122	Ureteral and Multifocal Tumours Have Worse Prognosis than Renal Pelvic Tumours in Urothelial Carcinoma of the Upper Urinary Tract Treated by Nephroureterectomy. <i>European Urology</i> , 2011, 60, 1258-1265.	0.9	147
123	Fine mapping the KLK3 locus on chromosome 19q13.33 associated with prostate cancer susceptibility and PSA levels. <i>Human Genetics</i> , 2011, 129, 675-685.	1.8	50
124	Pathological findings and oncological control afforded by radical prostatectomy in men with high-risk prostate cancer: a single-centre study. <i>World Journal of Urology</i> , 2011, 29, 665-670.	1.2	5
125	Oncologic control obtained after exclusive flexible ureteroscopic management of upper urinary tract urothelial cell carcinoma. <i>World Journal of Urology</i> , 2010, 28, 151-156.	1.2	97
126	Tissue expression of IL16 in prostate cancer and its association with recurrence after radical prostatectomy. <i>Prostate</i> , 2010, 70, 1622-1627.	1.2	22



#	ARTICLE	IF	CITATIONS
127	A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. <i>Nature Genetics</i> , 2010, 42, 978-984.	9.4	493
128	Methylated genes as potential biomarkers in prostate cancer. <i>BJU International</i> , 2010, 105, 1364-1370.	1.3	67
129	Micropapillary urothelial carcinoma of the urinary bladder: a clinicopathological analysis of 72 cases. <i>Pathology</i> , 2010, 42, 650-654.	0.3	111
130	Prostate-sparing Cystectomy for Bladder Cancer: A Step Toward a Dead-end. <i>Urology</i> , 2010, 76, 260-263.	0.5	8
131	Aurora-A/STK-15 Is Differentially Expressed in the Micropapillary Variant of Bladder Cancer. <i>Urologia Internationalis</i> , 2009, 82, 312-317.	0.6	9
132	Full analysis of the prostatic urethra at the time of radical cystoprostatectomy for bladder cancer: impact on final disease stage. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2009, 455, 449-453.	1.4	6
133	Oncologic outcome after radical prostatectomy in men with PSA values above 20Âng/ml: a monocentric experience. <i>World Journal of Urology</i> , 2009, 27, 653-658.	1.2	18
134	Oncological control after radical prostatectomy in men with clinical T3 prostate cancer: a single-centre experience. <i>BJU International</i> , 2009, 103, 1173-1178.	1.3	44
135	Cross-cultural validation of a prognostic tool: example of the Kattan preoperative nomogram as a predictor of prostate cancer recurrence after radical prostatectomy. <i>BJU International</i> , 2009, 104, 813-818.	1.3	16
136	Interest of methylated genes as biomarkers in urothelial cell carcinomas of the urinary tract. <i>BJU International</i> , 2009, 104, 896-901.	1.3	48
137	Promoter hypermethylation in circulating blood cells identifies prostate cancer progression. <i>International Journal of Cancer</i> , 2008, 122, 952-956.	2.3	77
138	Multiple loci identified in a genome-wide association study of prostate cancer. <i>Nature Genetics</i> , 2008, 40, 310-315.	9.4	871
139	A comparison of the performance of microsatellite and methylation urine analysis for predicting the recurrence of urothelial cell carcinoma, and definition of a set of markers by Bayesian network analysis. <i>BJU International</i> , 2008, 101, 1448-1453.	1.3	49
140	Molecular and histological markers in urothelial carcinomas of the upper urinary tract. <i>BJU International</i> , 2008, 102, 532-535.	1.3	53
141	Upper Urinary Tract Urothelial Cell Carcinomas and Other Urological Malignancies Involved in the Hereditary Nonpolyposis Colorectal Cancer (Lynch Syndrome) Tumor Spectrum. <i>European Urology</i> , 2008, 54, 1226-1236.	0.9	165
142	Gene Expression Study of Aurora-A Reveals Implication During Bladder Carcinogenesis and Increasing Values in Invasive Urothelial Cancer. <i>Urology</i> , 2008, 72, 873-877.	0.5	26
143	Effect of Genetic Variability within 8q24 on Aggressiveness Patterns at Diagnosis and Familial Status of Prostate Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 5635-5639.	3.2	30
144	Phenol Sulfotransferase SULT1A1*2 Allele and Enhanced Risk of Upper Urinary Tract Urothelial Cell Carcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007, 16, 2500-2503.	1.1	24

#	ARTICLE	IF	CITATIONS
145	Molecular Detection of Localized Prostate Cancer Using Quantitative Methylation-Specific PCR on Urinary Cells Obtained Following Prostate Massage. <i>Clinical Cancer Research</i> , 2007, 13, 1720-1725.	3.2	139
146	Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. <i>Nature Genetics</i> , 2007, 39, 645-649.	9.4	1,059
147	Relevance of the prostate-specific antigen (PSA) nanotest compared to the classical PSA test in the organized mass screening of prostate cancer. <i>BJU International</i> , 2007, 99, 762-764.	1.3	3
148	Upper Urinary Tract Transitional Cell Carcinoma: Recurrence Rate after Percutaneous Endoscopic Resection. <i>European Urology</i> , 2007, 51, 709-714.	0.9	101
149	Combination of Polymorphisms From Genes Related to Estrogen Metabolism and Risk of Prostate Cancers: The Hidden Face of Estrogens. <i>Journal of Clinical Oncology</i> , 2007, 25, 3596-3602.	0.8	89
150	Outcome after radical prostatectomy in young men with or without a family history of prostate cancer. <i>Urology</i> , 2006, 67, 1028-1032.	0.5	18
151	Comparison of open nephroureterectomy and ureteroscopic and percutaneous management of upper urinary tract transitional cell carcinoma. <i>Urology</i> , 2006, 67, 1181-1187.	0.5	128
152	Low penetrance genetic susceptibility to kidney cancer. <i>BJU International</i> , 2006, 98, 735-738.	1.3	7
153	Accuracy of the routine detection of mutation in mismatch repair genes in patients with susceptibility to hereditary upper urinary tract transitional cell carcinoma. <i>BJU International</i> , 2005, 96, 149-151.	1.3	13
154	Microsatellite instability and transitional cell carcinoma of the upper urinary tract. <i>BJU International</i> , 2005, 96, 489-492.	1.3	32
155	Genetic susceptibility to prostate cancer. <i>BJU International</i> , 2005, 96, 1380-1385.	1.3	24
156	Tissue Microarray Analysis of the Prognostic Value of E-Cadherin, Ki67, p53, p27, Survivin and MSH2 Expression in Upper Urinary Tract Transitional Cell Carcinoma. <i>European Urology</i> , 2005, 48, 764-770.	0.9	81
157	Differential expression of 37 selected genes in hormone refractory prostate cancer using quantitative taqman real-time RT-PCR. <i>International Journal of Cancer</i> , 2005, 114, 174-181.	2.3	26
158	Microsatellite instability as predictor of survival in patients with invasive upper urinary tract transitional cell carcinoma. <i>Urology</i> , 2005, 65, 1233-1237.	0.5	79
159	Microsatellite Instability in Urothelial Carcinoma of the Upper Urinary Tract. <i>Journal of Urology</i> , 2003, 170, 1151-1154.	0.2	51
160	Familial prostate cancer cases before and after radical prostatectomy do not show any aggressiveness compared with sporadic cases. <i>Urology</i> , 2003, 61, 1193-1197.	0.5	30
161	Targeted Screening For Prostate Cancer In High Risk Families: Early Onset Is A Significant Risk Factor For Disease In First Degree Relatives. <i>Journal of Urology</i> , 2002, 168, 483-487.	0.2	41
162	Non-invasive molecular detection of bladder cancer recurrence. <i>International Journal of Cancer</i> , 2002, 101, 293-297.	2.3	45

#	ARTICLE	IF	CITATIONS
163	Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways. <i>Cancer</i> , 2001, 92, 1130-1137.	2.0	161
164	htert expression correlates with MYC over-expression in human prostate cancer. <i>International Journal of Cancer</i> , 2000, 89, 172-176.	2.3	80
165	Early onset and familial predisposition to prostate cancer significantly enhance the probability for breast cancer in first degree relatives. <i>International Journal of Cancer</i> , 2000, 86, 883-887.	2.3	43
166	Early-onset hereditary prostate cancer is not associated with specific clinical and biological features. <i>Prostate</i> , 2000, 45, 66-71.	1.2	58
167	Assessment of microsatellite instability in urine in the detection of transitional cell carcinoma of the bladder. <i>International Journal of Cancer</i> , 1998, 79, 629-633.	2.3	2
168	Laser Induced Autofluorescence Diagnosis of Bladder Tumors: Dependence on the Excitation Wavelength. <i>Journal of Urology</i> , 1996, 156, 1590-1596.	0.2	60